Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Cutter & CO Brokerage Inc.

Cutter & CO Brokerage Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 7,958 shares of the biopharmaceutical company’s stock after buying an additional 293 shares during the quarter. Regeneron Pharmaceuticals comprises about 1.4% of Cutter & CO Brokerage Inc.’s holdings, making the stock its 16th biggest position. Cutter & CO Brokerage Inc.’s holdings in Regeneron Pharmaceuticals were worth $5,669,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Lake Street Advisors Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 9.3% in the fourth quarter. Lake Street Advisors Group LLC now owns 779 shares of the biopharmaceutical company’s stock valued at $555,000 after purchasing an additional 66 shares in the last quarter. Birinyi Associates Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $1,478,000. Sterling Investment Advisors Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 23.5% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 3,762 shares of the biopharmaceutical company’s stock valued at $2,680,000 after purchasing an additional 715 shares in the last quarter. FourThought Financial Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $435,000. Finally, Pine Valley Investments Ltd Liability Co lifted its holdings in shares of Regeneron Pharmaceuticals by 24.7% in the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 6,612 shares of the biopharmaceutical company’s stock valued at $4,710,000 after purchasing an additional 1,309 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on REGN shares. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Barclays reduced their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ:REGN opened at $723.47 on Wednesday. The company has a market cap of $79.09 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.34 and a beta of 0.08. The stock’s 50-day moving average is $698.84 and its 200-day moving average is $875.48. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $11.86 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.